Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Antisense oligonucleotide targeting TGF-beta2 shows promise for malignant glioma, other solid tumors

May 24, 2002

Zycos and Pharmexa sign cancer vaccine formulation agreement

May 17, 2002

Remitogen enters phase I solid tumor trial

May 16, 2002

FDA requests Provenge composition information from Dendreon

May 9, 2002

IL-13-PE38 granted fast track designation for malignant glioma

May 7, 2002

Gene-modified autologous tumor cell vaccine tested in patients with metastatic renal cell carcinoma

May 6, 2002

CancerVax puts hold on new patient enrollment in Canvaxin trial

May 3, 2002

Patient enrollment begins in pivotol Phase III Oncophage for melanoma study

May 3, 2002

Avicine set to enter phase III in pancreatic cancer

May 3, 2002

CpG-7909 enters phase I/II trial in stage IV renal cell carcinoma

May 2, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...